For Immediate Release
Is There a Benefit to Switching from Flash Monitoring to RT-CGM for Reducing Time in Hypoglycemia?
Contact: Kathryn Ryan
New Rochelle, NY, October 11, 2018—In follow-up to the I HART CGM study, which showed the benefit of real-time continuous glucose monitoring (RT-CGM) compared to flash monitoring for time spent in hypoglycemia among adults with type 1 diabetes at high hypoglycemia risk, researchers conducted an extension trial that assessed the effects of continuing RT-CGM or switching from flash to RT-CGM of the subsequent 8 weeks. The study design and results are published in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the full-text article free on the Diabetes Technology & Therapeutics (DTT) website.
Monika Reddy, Narvada Jugnee, Sinthuka Anantharaja, and Nick Oliver, Imperial College London, U.K. coauthored the study entitled “Switching from Flash Glucose Monitoring to Continuous Glucose Monitoring on Hypoglycemia in Adults with Type 1 Diabetes at High Hypoglycemia Risk: The Extension Phase of the I HART CGM Study.”
The extension study included 40 adults with T1D on intensified multiple daily insulin injections and with either impaired awareness of hypoglycemia or a recent episode of severe hypoglycemia. While both RT-CGM and flash monitoring measure interstitial fluid glucose, only RT-CGM has built-in alarms to let users know of the risk of an impending hypoglycemic event
The researchers reported a significant reduction in time in hypoglycemia among the subjects switching from flash to RT-CGM. Subjects continuing with RT-CGM for the additional 8 weeks maintained the benefits of that option related to hypoglycemia.
"Patients with a history of severe hypoglycemia associated with hypoglycemia unawareness would benefit from ‘alarms and alerts,’ and thus it makes sense that using a RT-CGM would show benefit in hypoglycemia reduction in this high risk population compared to using a device without alert features like flash glucose monitoring,” says DTT Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver (Aurora).
About the Journal
Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website. DTT is the official journal of the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD).
The International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) presents top caliber scientific programs that have provided participants with cutting-edge research and analysis into the latest developments in diabetes-related technology. A unique and innovative conference, ATTD brings the world’s leading researchers and clinicians together for a lively exchange of ideas and information related to the technology, treatment, and prevention of diabetes and related illnesses.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Thyroid, Metabolic Syndrome and Related Disorders, Journal of Aerosol Medicine and Pulmonary Drug Delivery, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.